Resistant starch for modulation of gut microbiota: Promising adjuvant therapy for chronic kidney disease patients?

32Citations
Citations of this article
133Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The gut microbiota has been extensively studied in all health science fields because its imbalance is linked to many disorders, such as inflammation and oxidative stress, thereby contributing to cardiovascular disease, obesity, diabetes and chronic kidney disease (CKD) complications. Novel therapeutic strategies that aim to reduce the complications caused by this imbalance have increased in recent years. Studies have shown that prebiotic supplementation can beneficially modulate the gut microbiota in CKD patients. Prebiotics consist of non-digestible dietary soluble fiber, which acts as a substrate for the gut microbiota. Resistant starch (RS) is a type of dietary fiber that can reach the large bowel and act as a substrate for microbial fermentation; for these reasons, it has been considered to be a prebiotic. Few studies have analyzed the effects of RS on the gut microbiota in CKD patients. This review discusses recent information about RS and the potential role of the gut microbiota, with a particular emphasis on CKD patients.

Cite

CITATION STYLE

APA

Moraes, C., Borges, N. A., & Mafra, D. (2016, August 1). Resistant starch for modulation of gut microbiota: Promising adjuvant therapy for chronic kidney disease patients? European Journal of Nutrition. Dr. Dietrich Steinkopff Verlag GmbH and Co. KG. https://doi.org/10.1007/s00394-015-1138-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free